Description
| Description | Zoliflodacin (ETX0914) (ETX0914, AZD0914) is a new bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus (MIC90: 0.25 μg/mL). |
| Targets&IC50 | S. aureus:0.25 μg/mL (MIC90) |
| In vitro | Zoliflodacin has antibacterial activity against key Gram-positive, fastidious Gram-negative (Haemophilus influenzae, Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones. Zoliflodacin stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA. |
| Synonyms | ETX0914, AZD0914 |
| Molecular Weight |
487.44 |
| Formula | C22H22FN5O7 |
| CAS No. | 1620458-09-4 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 135 mg/mL (276.95 mM),
Sonication is recommended.
